Deutsche Bank (ETR:DBKGn) initiated coverage on Acadia Pharmaceuticals (NASDAQ:ACAD) with a Hold rating and a price target of $22.00. The firm's analysts highlighted the arrival of a new CEO, ...
11d
Analyst Marc Goodman of Leerink Partners maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of ...
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company with a market capitalization of $3.06 billion, focuses on developing and commercializing innovative medicines to address unmet ...
The company's first drug candidate trofinetide – marketed as DAYBUE – is approved by the FDA and Health Canada for the ...
It's not easy to deal with tragedy, but for Colin Endres and the D-Y/CCT/CCA boys hockey team, they're honoring his sister Jillian's memory.
Taysha Gene Therapies offers hope for Rett syndrome with innovative treatment, strong trial results, and promising regulatory path. See more on TSHA stock here.
NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, ...
What is Zollinger-Ellison syndrome? Zollinger-Ellison syndrome (ZES) is a rare digestive disorder. If you have ZES, you likely have 1 or more tumors in the first part of the small intestine, the ...
Achieving the milestone will require the company’s two marketed products, Parkinson’s disease-related psychosis med Nuplazid and newer Rett syndrome treatment Daybue, to continue on their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback